Gao Zhang, Ph.D.
Affiliations: | 2012 | Bioengineering | University of Pennsylvania, Philadelphia, PA, United States |
Area:
Biomedical Engineering, Oncology, Cell BiologyGoogle:
"Gao Zhang"Parents
Sign in to add mentorMeenhard Herlyn | grad student | 2012 | Penn | |
(Induction of cellular senescence as a novel therapeutic strategy for melanoma treatment.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Zhang L, Jiang Y, Zhang G, et al. (2023) The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma. Frontiers in Immunology. 14: 1238233 |
Sun Y, Revach OY, Anderson S, et al. (2023) Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature |
Wei S, Yin D, Yu S, et al. (2022) Anti-tumor Activity of a Mitochondrial Targeted HSP90 Inhibitor in Gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Wang H, Chen H, Liu S, et al. (2021) Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function. Journal For Immunotherapy of Cancer. 9 |
Du K, Wei S, Wei Z, et al. (2021) Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. Nature Communications. 12: 6023 |
Yu S, Wei S, Savani M, et al. (2021) A Modified Nucleoside 6-thio-2'-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Liu J, Rebecca VW, Kossenkov AV, et al. (2021) Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance. Cancer Research |
Wang B, Zhang W, Zhang G, et al. (2021) Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene |
Liu D, Lin JR, Robitschek EJ, et al. (2021) Evolution of delayed resistance to immunotherapy in a melanoma responder. Nature Medicine |
Wang L, Gao Y, Zhang G, et al. (2020) Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. Science Translational Medicine. 12 |